{"id":69939,"date":"2026-07-14T14:44:58","date_gmt":"2026-07-14T06:44:58","guid":{"rendered":"https:\/\/flcube.com\/?p=69939"},"modified":"2026-07-14T14:45:00","modified_gmt":"2026-07-14T06:45:00","slug":"hengrui-pharmaceuticals-secures-nmpa-breakthrough-therapy-designation-for-hrs-7058-in-kras-g12c-mutant-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69939","title":{"rendered":"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its <strong>Category 1 chemical drug HRS-7058 capsules<\/strong> have received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from China&#8217;s <strong>Center for Drug Evaluation (CDE)<\/strong> under the <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>locally advanced or metastatic pancreatic cancer with KRAS G12C mutations<\/strong> in patients who have failed at least one prior line of systemic therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>HRS-7058 capsules \u2013 Category 1 chemical drug<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced\/metastatic pancreatic cancer with KRAS G12C mutations<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Post-first-line systemic therapy failure<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Novel, potent, selective small-molecule covalent KRAS G12C inhibitor<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-clinical-data\" class=\"wp-block-heading\">Drug Profile &amp; Clinical Data<\/h2>\n\n\n\n<h3 id=\"h-hrs-7058-targeted-kras-g12c-inhibitor\" class=\"wp-block-heading\">HRS-7058 \u2013 Targeted KRAS G12C Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Small-molecule covalent inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> KRAS G12C mutation (specifically targets the G12C variant)<\/li>\n\n\n\n<li><strong>Classification:<\/strong> Category 1 chemical drug (China&#8217;s highest innovation tier)<\/li>\n\n\n\n<li><strong>Broader Indication:<\/strong> Advanced solid tumors harboring KRAS G12C mutations<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Phase I completed, BTD granted based on clinical data<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-phase-i-clinical-results\" class=\"wp-block-heading\">Phase I Clinical Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Demonstrated clinically meaningful activity in later-line pancreatic cancer treatment<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Generally manageable with standard supportive care<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Heavily pre-treated advanced pancreatic cancer patients<\/li>\n\n\n\n<li><strong>Significance:<\/strong> Addresses critical unmet need in one of oncology&#8217;s most challenging tumor types<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Pancreatic cancer represents one of the most lethal malignancies, with a five-year survival rate of approximately 12%. The KRAS G12C mutation, while less common in pancreatic cancer (1-2% of cases) compared to lung cancer (13%), represents a validated therapeutic target with significant clinical implications for this molecularly-defined subset.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>KRAS Target Validation<\/strong><\/td><td>Previously considered &#8220;undruggable,&#8221; KRAS G12C inhibitors represent breakthrough class following sotorasib (Lumakras) and adagrasib (Krazati) approvals<\/td><\/tr><tr><td><strong>Pancreatic Cancer Market<\/strong><\/td><td>Limited treatment options post-first-line; median overall survival of 6-9 months in refractory setting<\/td><\/tr><tr><td><strong>Competitive Position<\/strong><\/td><td>HRS-7058 would be among first KRAS G12C inhibitors specifically evaluated in pancreatic cancer population<\/td><\/tr><tr><td><strong>Global Potential<\/strong><\/td><td>Success in China could support international development given unmet need globally<\/td><\/tr><tr><td><strong>Addressable Population<\/strong><\/td><td>Estimated 1,500-2,000 KRAS G12C-mutant pancreatic cancer patients annually in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development Pathway:<\/strong> BTD provides expedited review, intensive guidance, and potential priority approval pathway<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Premium pricing potential for targeted therapy addressing high-unmet-need indication<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Demonstrates Hengrui&#8217;s capability to develop world-class targeted oncology therapeutics<\/li>\n\n\n\n<li><strong>Investor Confidence:<\/strong> Reinforces Hengrui&#8217;s position as China&#8217;s leading innovative pharmaceutical company<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Success could position HRS-7058 for international partnerships or direct global development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The KRAS G12C inhibitor market is projected to reach $3.5 billion globally by 2030, with pancreatic cancer representing a high-value niche indication due to limited alternatives and poor prognosis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory pathways, clinical development, and commercial potential for HRS-7058. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260714_FEBR.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260714_FEBR.\"><\/object><a id=\"wp-block-file--media-b70e20d0-0992-453c-86d5-8b1d2b999849\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260714_FEBR.pdf\">600276_20260714_FEBR<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600276_20260714_FEBR.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b70e20d0-0992-453c-86d5-8b1d2b999849\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[34,2586,4228,852],"class_list":["post-69939","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China&#039;s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69939\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China&#039;s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69939\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T06:44:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T06:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69939#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69939\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer\",\"datePublished\":\"2026-07-14T06:44:58+00:00\",\"dateModified\":\"2026-07-14T06:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69939\"},\"wordCount\":500,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69939#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69939\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69939\",\"name\":\"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T06:44:58+00:00\",\"dateModified\":\"2026-07-14T06:45:00+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69939#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69939\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69939#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69939","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.","og_url":"https:\/\/flcube.com\/?p=69939","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T06:44:58+00:00","article_modified_time":"2026-07-14T06:45:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69939#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69939"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer","datePublished":"2026-07-14T06:44:58+00:00","dateModified":"2026-07-14T06:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69939"},"wordCount":500,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69939#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69939","url":"https:\/\/flcube.com\/?p=69939","name":"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T06:44:58+00:00","dateModified":"2026-07-14T06:45:00+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical drug HRS-7058 capsules have received Breakthrough Therapy Designation (BTD) from China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic pancreatic cancer with KRAS G12C mutations in patients who have failed at least one prior line of systemic therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69939#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69939"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69939#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69939"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69939\/revisions"}],"predecessor-version":[{"id":69941,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69939\/revisions\/69941"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}